1.Anemia Screening, Prevalence, and Treatment in Pediatric Inflammatory Bowel Disease in the United States, 2010–2014
Steven D MILLER ; Carmelo CUFFARI ; Eboselume AKHUEMONKHAN ; Anthony L GUERRERIO ; Harold LEHMANN ; Susan HUTFLESS
Pediatric Gastroenterology, Hepatology & Nutrition 2019;22(2):152-161
PURPOSE: We examined the prevalence of anemia, annual screening for anemia, and treatment of anemia with iron among children with inflammatory bowel disease (IBD). METHODS: A retrospective study of U.S. pediatric patients with IBD was performed in the MarketScan commercial claims database from 2010–2014. Children (ages 1–21) with at least two inpatient or outpatient encounters for IBD who had available lab and pharmacy data were included in the cohort. Anemia was defined using World Health Organization criteria. We used logistic regression to determine differences in screening, incident anemia, and treatment based on age at first IBD encounter and sex. RESULTS: The cohort (n=2,446) included 1,560 Crohn's disease (CD) and 886 ulcerative colitis (UC). Approximately, 85% of CD and 81% of UC were screened for anemia. Among those screened, 51% with CD and 43% with UC had anemia. Only 24% of anemia patients with CD and 20% with UC were tested for iron deficiency; 85% were iron deficient. Intravenous (IV) iron was used to treat 4% of CD and 4% UC patients overall and 8% of those with anemia. CONCLUSION: At least 80% of children with IBD were screened for anemia, although most did not receive follow-up tests for iron deficiency. The 43%–50% prevalence of anemia was consistent with prior studies. Under-treatment with IV iron points to a potential target for quality improvement.
Anemia
;
Child
;
Cohort Studies
;
Colitis, Ulcerative
;
Crohn Disease
;
Follow-Up Studies
;
Humans
;
Inflammatory Bowel Diseases
;
Inpatients
;
Iron
;
Logistic Models
;
Mass Screening
;
Outpatients
;
Pharmacy
;
Prevalence
;
Quality Improvement
;
Retrospective Studies
;
United States
;
World Health Organization
2.Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report
Altaf MOHAMMED ; Roderick H. DASHWOOD ; Sally DICKINSON ; Mary L. DISIS ; Elizabeth M. JAFFEE ; Bryon D. JOHNSON 6 ; Samir N. KHLEIF ; Michael N. POLLAK ; Jeffrey SCHLOM ; Robert H. SHOEMAKER ; Sasha E. STANTON ; Georg T. WONDRAK ; Ming YOU ; Hao ZHU ; Mark Steven MILLER
Journal of Cancer Prevention 2021;26(4):309-317
The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) convened the “Translational Advances in Cancer Prevention Agent Development (TACPAD) Workshop on Immunomodulatory Agents” as a virtual 2-day workshop on September 13 to 14, 2021. The main goals of this workshop were to foster the exchange of ideas and potentially new collaborative interactions among leading cancer immunoprevention researchers from basic and clinical research and highlight new and emerging trends in immunoprevention. The workshop included an overview of the mechanistic classes of immunomodulatory agents and three sessions covering the gamut from preclinical to clinical studies. The workshop convened individuals working in immunology and cancer prevention to discuss trends in discovery and development of immunomodulatory agents individually and in combination with other chemopreventive agents or vaccines.
3.Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting
Mark Steven MILLER ; Peter J. ALLEN ; Powel H. BROWN ; Andrew T. CHAN ; Margie L. CLAPPER ; Roderick H. DASHWOOD ; Shadmehr DEMEHRI ; Mary L. DISIS ; Raymond N. DUBOIS ; Robert J. GLYNN ; Thomas W. KENSLER ; Seema A. KHAN ; Bryon D. JOHNSON ; Karen T. LIBY ; Steven M. LIPKIN ; Susan R. MALLERY ; Emmanuelle J. MEUILLET ; Richard B.S. RODEN ; Robert E. SCHOEN ; Zelton D. SHARP ; Haval SHIRWAN ; Jill M. SIEGFRIED ; Chinthalapally V. RAO ; Ming YOU ; Eduardo VILAR ; Eva SZABO ; Altaf MOHAMMED
Journal of Cancer Prevention 2021;26(1):71-82
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.
4.Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting
Mark Steven MILLER ; Peter J. ALLEN ; Powel H. BROWN ; Andrew T. CHAN ; Margie L. CLAPPER ; Roderick H. DASHWOOD ; Shadmehr DEMEHRI ; Mary L. DISIS ; Raymond N. DUBOIS ; Robert J. GLYNN ; Thomas W. KENSLER ; Seema A. KHAN ; Bryon D. JOHNSON ; Karen T. LIBY ; Steven M. LIPKIN ; Susan R. MALLERY ; Emmanuelle J. MEUILLET ; Richard B.S. RODEN ; Robert E. SCHOEN ; Zelton D. SHARP ; Haval SHIRWAN ; Jill M. SIEGFRIED ; Chinthalapally V. RAO ; Ming YOU ; Eduardo VILAR ; Eva SZABO ; Altaf MOHAMMED
Journal of Cancer Prevention 2021;26(1):71-82
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.